Home/Daxor/Robert J. Michel
RJ

Robert J. Michel

Chief Financial Officer

Daxor

Daxor Pipeline

DrugIndicationPhase
BVA for Heart Failure ManagementHeart Failure (HFpEF/HFrEF)Commercial
BVA for Critical Care/ICUSepsis, Septic Shock, ARDSCommercial
BVA for Surgical Blood LossPerioperative & Surgical SettingsCommercial
BVA for SyncopeUnexplained SyncopeCommercial
BVA for Cardiorenal SyndromeHeart Failure with Renal DysfunctionResearch